Logo of Inoviq (ASX:IIQ)Latest Inoviq (ASX:IIQ) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

INOVIQ wins Sonic validation pathway for US ovarian cancer test

INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
2 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

INOVIQ Rebuilds Ovarian Cancer Test Path After Study Sample Failure

INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
Ada Torres
29 Oct 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

INOVIQ Flags Sample Quality Issues in EXO-OC Study, Commits to Strategic Review

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.
Ada Torres
14 July 2026

INOVIQ Faces Sample Setback but Advances EXO-OC Algorithm and CAR-Exosome Therapy

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.
Ada Torres
13 July 2026

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.
Logan Eniac
27 June 2026

INOVIQ’s CAR-Exosomes Achieve Up to 90% Tumour Kill in Ovarian Cancer Cells

INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.
Ada Torres
25 June 2026

Healthcare Wrap - Week 25 (15 June -> 19 June) 2026

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.
Logan Eniac
20 June 2026

INOVIQ Links Share Price Rise to Third-Party Research Highlighting Clinical Milestones

INOVIQ Limited confirms no undisclosed price-sensitive information amid recent share price surge, attributing the move to external research spotlighting upcoming EXO-OC ovarian cancer test data.
Ada Torres
17 June 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026